The overall uptake of RSV vaccine is low during its first season in those aged 60 years or older in the United States. The ...

A combination shot for flu and COVID-19 using messenger RNA generated antibodies in a study, but U.S. government regulators ...

A comprehensive new study reveals that respiratory syncytial virus (RSV) vaccines provide strong protection for adults aged 60 and older, with approximately 75% effectiveness against RSV-associated ...

Often thought of as only being dangerous to babies and toddlers due to how often child-related RSV spikes are in the news, the virus is actually just as worrisome in older adults. In fact ...

A new vaccine that combines flu and COVID-19 protection in one shot shows promising results, but the U.S. Food and Drug ...

Pfizer recorded $890 million in Abrysvo sales last year, although most of that came from its use to prevent RSV infections in older adults, a much larger market. RSV infections lead to more than ...

GSK is still on course with its clinical trials programme for vaccination against RSV in older adults, the larger market opportunity, but falling behind Pfizer in maternal immunisation is a blow ...

Infectious disease expert Elizabeth Wilson said RSV vaccination was now offered to every baby ... Pharmac did receive a funding application for the Arexvy vaccine for adults aged 60 and older in ...